• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 主蛋白酶的扩展构象揭示了别构靶标。

An extended conformation of SARS-CoV-2 main protease reveals allosteric targets.

机构信息

The Chinese Academy of Sciences Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Department of Biopharmaceutics, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.

出版信息

Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2120913119. doi: 10.1073/pnas.2120913119. Epub 2022 Mar 24.

DOI:10.1073/pnas.2120913119
PMID:35324337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9169858/
Abstract

SignificanceThe coronavirus main protease (M) is required for viral replication. Here, we obtained the extended conformation of the native monomer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) M by trapping it with nanobodies and found that the catalytic domain and the helix domain dissociate, revealing allosteric targets. Another monomeric state is termed compact conformation and is similar to one protomer of the dimeric form. We designed a Nanoluc Binary Techonology (NanoBiT)-based high-throughput allosteric inhibitor assay based on structural conformational change. Our results provide insight into the maturation, dimerization, and catalysis of the coronavirus M and pave a way to develop an anticoronaviral drug through targeting the maturation process to inhibit the autocleavage of M.

摘要

意义冠状病毒主蛋白酶 (M) 是病毒复制所必需的。在这里,我们通过纳米体捕获获得了严重急性呼吸系统综合征冠状病毒 2 (SARS-CoV-2) M 的天然单体的扩展构象,并发现催化结构域和螺旋结构域解离,揭示了变构靶标。另一种单体状态称为紧凑构象,类似于二聚体形式的一个单体。我们基于结构构象变化设计了基于 Nanoluc Binary Techonology (NanoBiT) 的高通量变构抑制剂测定法。我们的结果深入了解了冠状病毒 M 的成熟、二聚化和催化过程,并为通过靶向成熟过程来开发抑制 M 自身切割的抗冠状病毒药物铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/d459447b32c2/pnas.2120913119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/e94b11991584/pnas.2120913119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/ab05526eb392/pnas.2120913119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/4820ce42546d/pnas.2120913119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/41a7256688e9/pnas.2120913119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/d459447b32c2/pnas.2120913119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/e94b11991584/pnas.2120913119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/ab05526eb392/pnas.2120913119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/4820ce42546d/pnas.2120913119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/41a7256688e9/pnas.2120913119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59c/9169858/d459447b32c2/pnas.2120913119fig05.jpg

相似文献

1
An extended conformation of SARS-CoV-2 main protease reveals allosteric targets.SARS-CoV-2 主蛋白酶的扩展构象揭示了别构靶标。
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2120913119. doi: 10.1073/pnas.2120913119. Epub 2022 Mar 24.
2
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.SARS-CoV-2 主蛋白酶与非共价抑制剂 ML188 复合物的晶体结构
Viruses. 2021 Jan 25;13(2):174. doi: 10.3390/v13020174.
3
SARS-CoV-2 M inhibitors and activity-based probes for patient-sample imaging.SARS-CoV-2 M 抑制剂和基于活性的探针用于患者样本成像。
Nat Chem Biol. 2021 Feb;17(2):222-228. doi: 10.1038/s41589-020-00689-z. Epub 2020 Oct 22.
4
Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases.二聚化和N3结合对严重急性呼吸综合征冠状病毒(SARS-CoV)和新型冠状病毒(SARS-CoV-2)主要蛋白酶分子动力学的影响
J Biomol Struct Dyn. 2022 Sep;40(14):6243-6254. doi: 10.1080/07391102.2021.1880481. Epub 2021 Feb 2.
5
SARS-CoV-2 M oligomerization as a potential target for therapy.SARS-CoV-2 M 寡聚化作为一种潜在的治疗靶点。
Int J Biol Macromol. 2024 May;267(Pt 1):131392. doi: 10.1016/j.ijbiomac.2024.131392. Epub 2024 Apr 4.
6
Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.基于配体的虚拟筛选和小分子盲对接揭示了 SARS-CoV-2 主蛋白酶二聚体界面上的一个可能的靶位。
Comput Biol Chem. 2020 Dec;89:107372. doi: 10.1016/j.compbiolchem.2020.107372. Epub 2020 Sep 5.
7
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
8
The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.SARS-CoV-2 主蛋白酶的二聚体-单体平衡受小分子抑制剂影响。
Sci Rep. 2021 Apr 29;11(1):9283. doi: 10.1038/s41598-021-88630-9.
9
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.X射线筛选鉴定出新型冠状病毒主要蛋白酶的活性位点和变构抑制剂。
Science. 2021 May 7;372(6542):642-646. doi: 10.1126/science.abf7945. Epub 2021 Apr 2.
10
Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.基于结构的新型地衣化合物筛选对 SARS 冠状病毒主蛋白酶(Mpro)作为 COVID-19 的潜在抑制剂。
Mol Divers. 2021 Aug;25(3):1665-1677. doi: 10.1007/s11030-020-10118-x. Epub 2020 Jun 29.

引用本文的文献

1
Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations.通过分子动力学模拟揭示一种新型SARS-CoV-2 Mpro和PLpro天然双重抑制剂的作用机制。
Nat Prod Bioprospect. 2025 Jan 4;15(1):3. doi: 10.1007/s13659-024-00486-4.
2
A potential allosteric inhibitor of SARS-CoV-2 main protease (M) identified through metastable state analysis.通过亚稳态分析鉴定出的一种潜在的严重急性呼吸综合征冠状病毒2型主要蛋白酶(M)变构抑制剂。
Front Mol Biosci. 2024 Sep 6;11:1451280. doi: 10.3389/fmolb.2024.1451280. eCollection 2024.
3
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.

本文引用的文献

1
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.马替昔布是一种广谱冠状病毒 3CL 抑制剂,可阻断 SARS-CoV-2 的复制。
Science. 2021 Aug 20;373(6557):931-936. doi: 10.1126/science.abg5827. Epub 2021 Jul 20.
2
N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M Dimer.N 端指状结构稳定 SARS-CoV-2 M 二聚体中 S1 口袋,使猫科冠状病毒药物 GC376 可逆结合。
J Mol Biol. 2021 Jun 25;433(13):167003. doi: 10.1016/j.jmb.2021.167003. Epub 2021 Apr 22.
3
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
基于 VSV 系统筛选的 SARS-CoV-2 主蛋白酶(Mpro)抑制剂耐药突变体的综合研究。
PLoS Pathog. 2024 Sep 11;20(9):e1012522. doi: 10.1371/journal.ppat.1012522. eCollection 2024 Sep.
4
New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors.新型噻唑烷-4-酮衍生物作为严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂
Pharmaceuticals (Basel). 2024 May 17;17(5):650. doi: 10.3390/ph17050650.
5
Quantitative Assessment of Energetic Contributions of Residues in a SARS-CoV-2 Viral Enzyme/Nanobody Interface.定量评估 SARS-CoV-2 病毒酶/纳米抗体界面残基的能量贡献。
J Chem Inf Model. 2024 Mar 25;64(6):2068-2076. doi: 10.1021/acs.jcim.3c01933. Epub 2024 Mar 9.
6
A comprehensive study of SARS-CoV-2 main protease (M) inhibitor-resistant mutants selected in a VSV-based system.在基于水疱性口炎病毒(VSV)的系统中筛选出的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(M)抑制剂抗性突变体的综合研究。
bioRxiv. 2023 Oct 4:2023.09.22.558628. doi: 10.1101/2023.09.22.558628.
7
Sensitivity-enhanced nanoplasmonic biosensor using direct immobilization of two engineered nanobodies for SARS-CoV-2 spike receptor-binding domain detection.利用直接固定两种工程化纳米抗体检测SARS-CoV-2刺突受体结合域的灵敏度增强型纳米等离子体生物传感器。
Sens Actuators B Chem. 2023 May 15;383:133575. doi: 10.1016/j.snb.2023.133575. Epub 2023 Feb 24.
8
Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2.纳米抗体在预防、检测和治疗不断演变的 SARS-CoV-2 中的应用。
Biochem Pharmacol. 2023 Feb;208:115401. doi: 10.1016/j.bcp.2022.115401. Epub 2022 Dec 30.
9
Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro.SARS-CoV-2 多蛋白由 Mpro 加工的生化和结构见解。
Sci Adv. 2022 Dec 9;8(49):eadd2191. doi: 10.1126/sciadv.add2191.
10
Biofunctional roles of estrogen in coronavirus disease 2019: Beyond a steroid hormone.雌激素在2019冠状病毒病中的生物功能作用:超越类固醇激素。
Front Pharmacol. 2022 Oct 19;13:1003469. doi: 10.3389/fphar.2022.1003469. eCollection 2022.
X射线筛选鉴定出新型冠状病毒主要蛋白酶的活性位点和变构抑制剂。
Science. 2021 May 7;372(6542):642-646. doi: 10.1126/science.abf7945. Epub 2021 Apr 2.
4
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
5
Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.经系统中和抗体治疗后,鼻甲骨中出现稳健的 SARS-CoV-2 感染。
Cell Host Microbe. 2021 Apr 14;29(4):551-563.e5. doi: 10.1016/j.chom.2021.02.019. Epub 2021 Feb 25.
6
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
7
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
8
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.
9
Design and development of stapled transmembrane peptides that disrupt the activity of G-protein-coupled receptor oligomers.设计和开发用于破坏 G 蛋白偶联受体寡聚物活性的订书钉跨膜肽。
J Biol Chem. 2019 Nov 8;294(45):16587-16603. doi: 10.1074/jbc.RA119.009160. Epub 2019 Aug 29.
10
SARS and MERS: recent insights into emerging coronaviruses.严重急性呼吸综合征和中东呼吸综合征:对新型冠状病毒的最新见解
Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27.